NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs
Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells CAMBRIDGE, Mass. & LEVERKUSEN, Germany--(BUSINESS WIRE)--NextPoint Therapeutics, a biotechnology company developing a new world of precisi...